Navigation Links
Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
Date:11/10/2011

CAMBRIDGE, England, November 10, 2011 /PRNewswire/ --

Arecor, the leading company in advancing aqueous formulation solutions for proteins, peptides and vaccines, is pleased to announce the appointment of Dr Sarah Howell as Chief Operating Officer.  Dr Howell will be responsible for the operations of Arecor, with a focus on developing and maintaining Arecor's upward growth curve ensuring the company continues to deliver exceptional formulation solutions and performance to the highest standards across the industry.

Dr Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of products and therapeutic areas having worked in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had responsibility for CMC development and supply across BTG's diverse portfolio of products.  Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline.  She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.  Dr Howell has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.

Tom Saylor, CEO of Arecor stated "Sarah's considerable technical and leadership experience in the management of development programmes for biologic drugs, and her capabilities in building partnerships with major pharmaceutical companies will be a tremendous asset to Arecor as it expands its business in an industry looking to formulation as an enabling technology for the new generation of biologic drugs."

Arecor was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics.  Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products.  Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation.  As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

Contact:

Tom Saylor, CEO tsaylor@arecor.com
Arecor Ltd
2 Cambridge Science Park
Cambridge, UK
http://www.arecor.com
+44(0)1223-426060



'/>"/>
SOURCE Arecor
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
2. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
3. Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer
4. Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice
5. Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors
6. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
7. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
8. Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory
9. China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
10. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
11. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):